The role of somatostatin analogs in the management of medullary thyroid carcinoma.
Lupoli
G A
GA
Department of Molecular and Clinical Oncology and Endocrinology, Federico II University, Naples, Italy. lupoli@unina.it
Fonderico
F
F
Fittipaldi
M R
MR
Colarusso
S
S
Panico
A
A
Cavallo
A
A
Di Micco
L
L
Lupoli
G
G
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018276:Carcinoma, Medullary / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage; D015282:Octreotide / Q000008:administration & dosage; D010456:Peptides, Cyclic / Q000008:administration & dosage; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D007155:Immunologic Factors; D016898:Interferon-alpha; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide